{
  "nctId": "NCT05736939",
  "briefTitle": "Gender Differences in the Recovery Rate Following PR in Patients With Long COVID-19",
  "officialTitle": "Gender Differences in the Recovery Rate Following a Hybrid Pulmonary Rehabilitation Programme in Patients With Long COVID-19 Syndrome",
  "protocolDocument": {
    "nctId": "NCT05736939",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-04-01",
    "uploadDate": "2023-02-19T15:24",
    "size": 239704,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05736939/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 30,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2022-10-01",
    "completionDate": "2023-03-15",
    "primaryCompletionDate": "2023-02-28",
    "firstSubmitDate": "2023-02-19",
    "firstPostDate": "2023-02-21"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Hospitalisation due to Sars-COV-2 infection.\n* Presence of persistence fatigue assessed via FACIT questionnaire.\n\nExclusion Criteria:\n\nExclusion criteria include presence of any of the following list within 3 months prior to informed consent:\n\n* participation in another clinical trial\n* occurrence of myocardial infarction\n* hospitalisation for unstable angina\n* stroke\n* coronary artery bypass graft (CABG)\n* percutaneous coronary intervention (PCI)\n* implantation of a cardiac resynchronisation therapy device (CRTD)\n* active treatment for cancer or other malignant disease\n* uncontrolled congestive heart disease (NYHA class \\>3)\n* acute psychosis or major psychiatric disorders or continued substance abuse",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Fatigue",
        "description": "Degree of fatigue will be assessed via the Functional Assessment of Chronic Illness Therapy questionnaire",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      }
    ],
    "secondary": [
      {
        "measure": "Quadriceps muscle strength",
        "description": "Quadriceps muscle strength will be reported as maximum strength in kg",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Handgrip muscle strength",
        "description": "Handgrip muscle strength will be reported as maximum strength in kg",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Inspiratory muscle strength",
        "description": "Inspiratory muscle strength will be reported as maximum strength in centimeters water",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Expiratory muscle strength",
        "description": "Expiratory muscle strength will be reported as maximum strength in centimeters water",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Dyspnoea",
        "description": "Dyspnoea will be assessed via completion of modified Medical Research Council Dyspnoea Scale questionnaire. The score ranges from 0-4. The greater the score, the worse the dyspnoea levels",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Emotional status",
        "description": "Emotional status will be assessed via completion of the Hospital Anxiety and Depression. Scale questionnaire. The score ranges from 0-21 for each component (anxiety and depression). The higher the score, the higher the levels of anxiety and depression.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Symptoms",
        "description": "Symptoms will be assessed via completion of the Chronic Obstructive Pulmonary Disease Assessment Tool questionnaire. The score ranges from 0-40 points. The higher the score, the worse the prognosis.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Self-reported quality of life",
        "description": "Self-reported quality of life will be assessed via completion of the EuroQol-5Dimension-5Levels questionnaire.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Post traumatic stress disorder (PTSD)",
        "description": "PTSD will be assessed via completion of the Impact Event Scale-Revised questionnaire.The total score ranges from 0-88. The higher the score, the higher the levels of PTSD",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Six minute walk distance covered",
        "description": "The distance that patients cover during the six minute walk test.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Short Physical Performance Buttery test (SPPB)",
        "description": "SPPB is a series of test including balance, 4 meter walk and 5 sit-to-stand repetitions. The test assess the functional capacity of the patients.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Level of daily physical activity",
        "description": "Level of daily physical activity will be reported as steps per day the week prior the initiation of the intervention and one week following the completion of the intervention.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Exercise tolerance",
        "description": "Exercise tolerance will be assessed by performing a cardiopulmonary exercise test.",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      },
      {
        "measure": "Cardiac function",
        "description": "Cardiac function will be assessed via a resting echocardiography",
        "timeFrame": "Prior and following the completion of a 3 month pulmonary rehabilitation programme (At 0 and at 3 months)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 14,
      "otherCount": 0,
      "totalCount": 15
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:36.958Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}